{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:41:39Z","timestamp":1786650099069,"version":"build-2736575974"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2015,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Lenalidomide an immunomodulatory agent has shown activity in relapsed\/refractory lymphoma. This study was conducted to evaluate its efficacy and optimal dose in Indian patients with relapsed\/refractory lymphoma who were unable or unwilling to undergo autologous hematopoietic stem cell transplant.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>Patients received oral lenalidomide at 20 mg on days 1-21 every 28 days until disease progression or unacceptable toxicity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of 25 patients received lenalidomide at a starting dose of 20 mg. Majority of patients were diffuse large B-cell lymphoma (DLBCL). The overall response rate (ORR) was 48%, with 16% achieved complete remission (CR)\/unconfirmed CR (CRu), 32% partial response (PR) and 16% stable disease (SD) Among patients with DLBCL the ORR was of 33.3%; with CR\/CRu 20%, PR (13.3%), 20% had SD, progressive disease (PD) was seen in seven patients (46.6%). All follicular lymphoma patients responded to treatment, with CR in one patient and PR in other two. Among patients with mantle cell lymphoma, ORR was 75% with PR in (75%) and SD in 25%. One case of transformed lymphoma had a PR and peripheral T-cell lymphoma had no response to treatment. The median duration of response was 8.5 months, with a time to response of 3 months. Median progression free survival was not reached in responding patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Lenalidomide is an effective treatment option in relapsed refractory non hodgkin's lymphoma.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/0973-1482.151418","type":"journal-article","created":{"date-parts":[[2016,2,19]],"date-time":"2016-02-19T00:48:49Z","timestamp":1455842929000},"page":"857-861","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Lenalidomide in relapsed refractory non-Hodgkin\u2032s lymphoma: An Indian perspective"],"prefix":"10.4103","volume":"11","author":[{"given":"K. C.","family":"Lakshmaiah","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Bengaluru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. S.","family":"Rachan Shetty","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Bengaluru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishwanath","family":"Sathyanarayanan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Bengaluru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Lokanatha","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Bengaluru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linu Jacob","family":"Abraham","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Bengaluru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. Govinda","family":"Babu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Bengaluru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2016,2,15]]},"reference":[{"key":"R1-20260109","first-page":"433","article-title":"Trends in the incidence of Non-Hodgkin's lymphoma in India","volume":"9","author":"Yeole","year":"2008","journal-title":"Asian Pac J Cancer Prev"},{"key":"R2-20260109","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1053\/j.seminoncol.2005.01.008","article-title":"Lymphoma: Diagnosis, staging, natural history, and treatment strategies","volume":"32","author":"Zinzani","year":"2005","journal-title":"Semin Oncol"},{"key":"R3-20260109","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1182\/asheducation.V2012.1.410.3798518","article-title":"Is there any role for transplantation in the rituximab era for diffuse large B-cell lymphoma?","volume":"2012","author":"Gisselbrecht","year":"2012","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"R4-20260109","doi-asserted-by":"crossref","first-page":"3688","DOI":"10.1200\/JCO.2013.49.2835","article-title":"Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: Phase II MCL-001 (EMERGE) study","volume":"31","author":"Goy","year":"2013","journal-title":"J Clin Oncol"},{"key":"R5-20260109","doi-asserted-by":"crossref","first-page":"932010","DOI":"10.1155\/2013\/932010","article-title":"Lenalidomide and chronic lymphocytic leukemia","volume":"2013","author":"Gonz\u00e1lez-Rodr\u00edguez","year":"2013","journal-title":"Biomed Res Int"},{"key":"R6-20260109","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2147\/CMAR.S34273","article-title":"Treatment challenges in the management of relapsed or refractory non-Hodgkin's lymphoma-Novel and emerging therapies","volume":"5","author":"Chao","year":"2013","journal-title":"Cancer Manag Res"},{"key":"R7-20260109","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1200\/JCO.2008.19.9117","article-title":"Humanized anti-CD20 antibody, veltuzumab, in refractory\/recurrent non-Hodgkin's lymphoma: Phase I\/II results","volume":"27","author":"Morschhauser","year":"2009","journal-title":"J Clin Oncol"},{"key":"R8-20260109","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1200\/JCO.2006.05.6291","article-title":"Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma","volume":"24","author":"Strauss","year":"2006","journal-title":"J Clin Oncol"},{"key":"R9-20260109","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1182\/blood.V112.11.266.266","article-title":"Safety and clinical activity of the anti-CD22 immunoconjugate inotuzumab ozogamicin (CMC-544) in combination with rituximab in follicular lymphoma or diffuse large B-cell lymphoma: Preliminary report of a phase 1\/2 study","volume":"112","author":"Fayad","year":"2008","journal-title":"Blood"},{"key":"R10-20260109","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1053\/j.semnuclmed.2009.11.002","article-title":"Radioimmunotherapy of lymphoma: Bexxar and Zevalin","volume":"40","author":"Goldsmith","year":"2010","journal-title":"Semin Nucl Med"},{"key":"R11-20260109","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1182\/blood.V116.21.1777.1777","article-title":"Clinical safety and activity in a phase 1 study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110delta, in patients with relapsed or refractory non-Hodgkin lymphoma","volume":"166","author":"Kahl","year":"2010","journal-title":"Blood"},{"key":"R12-20260109","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","article-title":"Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies","volume":"31","author":"Advani","year":"2013","journal-title":"J Clin Oncol"},{"key":"R13-20260109","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1200\/JCO.2008.20.7977","article-title":"Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma","volume":"27","author":"Hess","year":"2009","journal-title":"J Clin Oncol"},{"key":"R14-20260109","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/leu.2010.226","article-title":"A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma","volume":"25","author":"Witzig","year":"2011","journal-title":"Leukemia"},{"key":"R15-20260109","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S1470-2045(10)70261-8","article-title":"Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: A phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity","volume":"11","author":"Wilson","year":"2010","journal-title":"Lancet Oncol"},{"key":"R16-20260109","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1200\/JCO.2010.32.1398","article-title":"Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma","volume":"29","author":"Kirschbaum","year":"2011","journal-title":"J Clin Oncol"},{"key":"R17-20260109","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","article-title":"Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma","volume":"24","author":"Fisher","year":"2006","journal-title":"J Clin Oncol"},{"key":"R18-20260109","doi-asserted-by":"crossref","first-page":"498342","DOI":"10.1155\/2012\/498342","article-title":"Lenalidomide in diffuse large B-cell lymphomas","volume":"2012","author":"Chiappella","year":"2012","journal-title":"Adv Hematol"},{"key":"R19-20260109","doi-asserted-by":"crossref","first-page":"4952","DOI":"10.1200\/JCO.2007.15.3429","article-title":"Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma","volume":"26","author":"Wiernik","year":"2008","journal-title":"J Clin Oncol"},{"key":"R20-20260109","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1093\/annonc\/mdq626","article-title":"An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma","volume":"22","author":"Witzig","year":"2011","journal-title":"Ann Oncol"},{"key":"R21-20260109","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.clml.2011.02.001","article-title":"Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: A phase 2 trial","volume":"11","author":"Zinzani","year":"2011","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R22-20260109","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S1470-2045(12)70200-0","article-title":"Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: A phase 1\/2 clinical trial","volume":"13","author":"Wang","year":"2012","journal-title":"Lancet Oncol"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01363817-201511040-00032","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:02:23Z","timestamp":1786647743000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01363817-201511040-00032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.4103\/0973-1482.151418","relation":{},"ISSN":["0973-1482","1998-4138"],"issn-type":[{"value":"0973-1482","type":"print"},{"value":"1998-4138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10]]}}}